Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES
ETHOSUXIMIDE CAPSULES, USP
Authorized Generic of ZARONTIN® (ethosuximide capsules)
and

ETHOSUXIMIDE ORAL SOLUTION
Authorized Generic of ZARONTIN® (ethosuximide capsules)
ORAL SOLUTION

PEAPACK, NJ, October 2015 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE), is pleased to announce the introduction of ethosuximide capsules and ethosuximide oral solution to its ever-expanding generic pharmaceutical product line. The capsules are offered in dosage strength of 250 mg in bottles of 100 counts, and the oral solution in a dosage strength of 250 mg/5 mL as oral solution.

Greenstone’s ethosuximide capsules product and ethosuximide oral solution products are the authorized generics of and equivalent to the innovator’s products, ZARONTIN (ethosuximide capsules) and ZARONTIN (ethosuximide) ORAL SOLUTION, respectively.

These new authorized generics add to Greenstone’s consistently growing line of products, and are backed by the distribution and customer service support of Pfizer Inc., one of the world’s premiere biopharmaceutical companies. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients it serves.

See the Full Prescribing Information for Greenstone’s ethosuximide capsules and ethosuximide oral solution at http://www.greenstonellc.com/product-list.aspx.

For more information about Greenstone LLC and its products, visit http://greenstonellc.com.

Zarontin is a registered trademark of Warner-Lambert Company LLC.